{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:52:09Z","timestamp":1792605129701,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:00:00Z","timestamp":1720137600000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ymthe.2023.03.019","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:27:39Z","timestamp":1679444859000},"page":"1874-1903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Zohreh","family":"Najminejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Dehghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Hussein","family":"Mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyed Amirreza","family":"Saghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohadeseh Haji","family":"Abdolvahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Meyfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Jahandideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohid","family":"Gharibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Amirkhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Delam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushin","family":"Mashatan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosein","family":"Shahsavarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghdad","family":"Abdollahpour-Alitappeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.03.019_bib1","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(96)07493-4","article-title":"Mortality by cause for eight regions of the world: global burden of disease study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2023.03.019_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","article-title":"Epidemiology of breast cancer","volume":"2","author":"Key","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2023.03.019_bib4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ymthe.2023.03.019_bib5","doi-asserted-by":"crossref","first-page":"113959","DOI":"10.1016\/j.bcp.2020.113959","article-title":"Drug uptake-based chemoresistance in breast cancer treatment","volume":"177","author":"Muley","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib6","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.ymthe.2023.03.019_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2023.03.019_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/13543784.2017.1315406","article-title":"Perspectives of HER2-targeting in gastric and esophageal cancer","volume":"26","author":"Gerson","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2023.03.019_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejps.2016.08.015","article-title":"HER2-targeted antibody drug conjugates for ovarian cancer therapy","volume":"93","author":"Jiang","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ymthe.2023.03.019_bib11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fonc.2012.00062","article-title":"Trastuzumab: updated mechanisms of action and resistance in breast cancer","volume":"2","author":"Vu","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib12","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/jcp.27085","article-title":"Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in\u00a0vitro against HER2-positive human breast cancer","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2010.01711.x","article-title":"Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer","volume":"102","author":"Mukohara","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ymthe.2023.03.019_bib14","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/annonc\/mdl475","article-title":"Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer","volume":"18","author":"Valabrega","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10555-022-10021-x","article-title":"Anti-HER2 therapy in metastatic breast cancer: many choices and future directions","volume":"41","author":"Wynn","year":"2022","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2023.03.019_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.4161\/cbt.11.9.15045","article-title":"Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications","volume":"11","author":"Garrett","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ctrv.2008.09.003","article-title":"HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors","volume":"35","author":"Nielsen","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ymthe.2023.03.019_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/acs.oprd.6b00067","article-title":"Processes for constructing homogeneous antibody drug conjugates","volume":"20","author":"Jackson","year":"2016","journal-title":"Org. Process. Res. Dev."},{"key":"10.1016\/j.ymthe.2023.03.019_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.ymthe.2023.03.019_bib21","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib24","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1021\/acsmedchemlett.6b00312","article-title":"Expanding the reach of antibody-drug conjugates","volume":"7","author":"Chari","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2023.03.019_bib26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.03.019_bib27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtho.2018.11.034","article-title":"Antibody-drug conjugates for the therapy of thoracic malignancies","volume":"14","author":"Xie","year":"2019","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib29","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib32","series-title":"Innovations for Next-Generation Antibody-Drug Conjugates","author":"Damelin","year":"2018"},{"key":"10.1016\/j.ymthe.2023.03.019_bib33","first-page":"e6036","article-title":"Long-time response with ado-trastuzumab emtansine in a recurrent metastatic breast cancer","volume":"11","author":"Manthri","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.ymthe.2023.03.019_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ymthe.2023.03.019_bib36","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib38","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13058-021-01459-y","article-title":"Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions","volume":"23","author":"Ferraro","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib40","series-title":"Single Agent Activity of DS-8201a, a HER2-Targeting Antibody-Drug Conjugate, in Heavily Pretreated HER2 Expressing Solid Tumors","author":"Doi","year":"2017"},{"key":"10.1016\/j.ymthe.2023.03.019_bib41","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS17-PD3-07","article-title":"Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers [abstract]","author":"Modi","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib42","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2020.38.15_suppl.1049","article-title":"A first in-human study of A166 in patients with locally advanced\/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies","volume":"38","author":"Liu","year":"2020","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib43","article-title":"Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors [abstract]","author":"Hu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib44","doi-asserted-by":"crossref","first-page":"B005","DOI":"10.1158\/1535-7163.TARG-19-B005","article-title":"Abstract B005: A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced\/metastatic solid tumors","volume":"18","author":"Lopez","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib45","doi-asserted-by":"crossref","first-page":"847835","DOI":"10.3389\/fmolb.2022.847835","article-title":"Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers","volume":"9","author":"Yu","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ymthe.2023.03.019_bib46","series-title":"First-in-human Phase I Study of ALT-P7, a HER2-Targeting Antibody-Drug Conjugate in Patients with HER2-Positive Advanced Breast Cancer","author":"Park","year":"2020"},{"key":"10.1016\/j.ymthe.2023.03.019_bib47","doi-asserted-by":"crossref","first-page":"12020","DOI":"10.1002\/anie.201505964","article-title":"Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy","volume":"54","author":"Lee","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2023.03.019_bib48","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/molecules25071515","article-title":"Quantification of an antibody-conjugated drug in fat plasma by an affinity capture LC-MS\/MS method for a novel prenyl transferase-mediated site-specific antibody-drug conjugate","volume":"25","author":"Lee","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2023.03.019_bib49","doi-asserted-by":"crossref","unstructured":"Deckert, J., Thirlway, J., Park, Y.-H., Song, H.Y., Chung, C.-W., Wang, X., Zhang, Z., and Lutz., R.J. (2022 Apr 8-13). IKS014, a HER2-targeting antibody drug conjugate incorporating novel bioconjugation and tumor-selective linker technology with improved in\u00a0vivo efficacy and tolerability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022. Cancer Research 82 (Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract Nr 1753.).","DOI":"10.1158\/1538-7445.AM2022-1753"},{"key":"10.1016\/j.ymthe.2023.03.019_bib51","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib52","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.03.019_bib53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.drudis.2021.10.008","article-title":"Multiple strategies for the treatment of invasive breast carcinoma: a comprehensive prospective","volume":"27","author":"Agarwal","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2023.03.019_bib54","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","article-title":"Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design","volume":"181","author":"Trail","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib55","article-title":"Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors [abstract]","author":"Zammarchi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib56","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2023.03.019_bib57","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(16)32662-4","article-title":"ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody\u2013drug conjugate (ADC) targeting low HER2-expressing solid cancers","volume":"69","author":"Zammarchi","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib59","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cac2.12135","article-title":"Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: an open-label, dose-escalation, phase I study","volume":"41","author":"Hong","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ymthe.2023.03.019_bib60","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib61","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","article-title":"Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin","volume":"15","author":"Austin","year":"2004","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ymthe.2023.03.019_bib62","article-title":"BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancer [abstract]","author":"Tang","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib63","first-page":"18","article-title":"Novel development strategies and challenges for anti-Her2 antibody-drug conjugates","volume":"5","author":"Zhang","year":"2022","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib64","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2023.03.019_bib65","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1158\/1535-7163.MCT-14-0040-T","article-title":"Preclinical profile of the HER2-targeting ADC SYD983\/SYD985: introduction of a new duocarmycin-based linker-drug platform","volume":"13","author":"Dokter","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib66","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The exciting new field of HER2-low breast cancer treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2023.03.019_bib67","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib68","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","article-title":"The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers","volume":"14","author":"van der Lee","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib69","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib70","doi-asserted-by":"crossref","first-page":"S1288","DOI":"10.1016\/j.annonc.2021.08.2088","article-title":"LBA15 Primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer","volume":"32","author":"Saura Manich","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib71","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.2020.38.15_suppl.3110","article-title":"SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist","volume":"38","author":"Metz","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib72","series-title":"317 A Phase 1\/1b Study of SBT6050, a HER2-Directed Monoclonal Antibody Conjugated to a Toll-like Receptor 8 Agonist, in Subjects with Advanced HER2-Expressing Solid Tumors","author":"Emens","year":"2020"},{"key":"10.1016\/j.ymthe.2023.03.019_bib73","doi-asserted-by":"crossref","first-page":"S1453","DOI":"10.1016\/j.annonc.2021.10.183","article-title":"164P Preliminary results from a phase I\/II study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors","volume":"32","author":"Sharma","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib74","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2021.39.15_suppl.2549","article-title":"Preliminary results from a phase 1\/2 study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors","volume":"39","author":"Sharma","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib75","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-OT-03-02","article-title":"Phase 1\/2 study of a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors [abstract]","author":"Dumbrava","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ymthe.2023.03.019_bib76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/antib8010011","article-title":"Multiplex LC-MS\/MS assays for clinical bioanalysis of MEDI4276, an antibody-drug conjugate of tubulysin analogue attached via cleavable linker to a biparatopic humanized antibody against HER-2","volume":"8","author":"Faria","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.ymthe.2023.03.019_bib78","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","article-title":"First-in-Human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib79","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ccell.2019.05.010","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"35","author":"Li","year":"2019","journal-title":"Cancer cell"},{"key":"10.1016\/j.ymthe.2023.03.019_bib80","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1093\/annonc\/mdy048.005","article-title":"Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer","volume":"29","author":"Pegram","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib81","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","article-title":"A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity","volume":"153","author":"Yao","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2023.03.019_bib82","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1080\/15384047.2016.1139248","article-title":"An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer","volume":"17","author":"Li","year":"2016","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib83","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2023.03.019_bib84","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a site-specific anti-HER2 antibody-drug conjugate, demonstrates potent and selective activity in HER2-low and T-DM1-resistant breast and gastric cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib85","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-639","article-title":"Site specific conjugation of ARX-788, an antibody drug conjugate (ADC) targeting HER2, generates a potent and stable targeted therapeutic for multiple cancers [abstract]","author":"Humphreys","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib86","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1158\/1535-7163.MCT-19-0692","article-title":"Nonclinical development of next-generation site-specific HER2-targeting antibody-drug conjugate (ARX788) for breast cancer treatment","volume":"19","author":"Nagaraja Shastri","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib87","doi-asserted-by":"crossref","first-page":"P1-18-P16","DOI":"10.1158\/1538-7445.SABCS19-P1-18-16","article-title":"Abstract P1-18-16: a phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer","volume":"80","author":"Hu","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib88","first-page":"175","article-title":"Preclinical evaluation of MRG002, a novel HER2-targeting antibody-drug conjugate with potent antitumor activity against HER2-positive solid tumors","volume":"4","author":"Li","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib89","series-title":"First-in-human Phase I Study of Anti-HER2 ADC MRG002 in Patients with Relapsed\/refractory Solid Tumors","author":"Li","year":"2020"},{"key":"10.1016\/j.ymthe.2023.03.019_bib90","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.2022.40.16_suppl.1102","article-title":"A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer","volume":"40","author":"Jiang","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2147\/OTT.S357326","article-title":"An innovative site-specific anti-HER2 antibody-drug conjugate with high homogeneity and improved therapeutic index","volume":"15","author":"Hui","year":"2022","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib92","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1158\/1535-7163.MCT-19-0207","article-title":"A novel anti-HER2 antibody-drug conjugate XMT-1522 for HER2-positive breast and gastric cancers resistant to trastuzumab emtansine","volume":"18","author":"Le Joncour","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib93","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: a novel antibody-drug conjugate platform featuring high drug loading and a controlled bystander effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS15-P4-14-28","article-title":"XMT-1522 induces tumor regressions in pre-clinical models representing HER2-positive and HER2 low-expressing breast cancer [abstract]","author":"Bergstrom","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib95","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-4","article-title":"Inhibitory effects of aprotinin on survival and local invasion of human breast cancer cell lines [abstract]","author":"Soleyman-Jahi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib96","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2015-LB-231","article-title":"A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors [abstract]","author":"Bergstrom","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib97","series-title":"Phase 1 Dose Escalation of XMT-1522, a Novel HER2-Targeting Antibody-Drug Conjugate (ADC), in Patients (Pts) with HER2-Expressing Breast, Lung and Gastric Tumors","author":"Hamilton","year":"2018"},{"key":"10.1016\/j.ymthe.2023.03.019_bib98","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-1738","article-title":"XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity [abstract]","volume":"81","author":"Duvall","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib99","doi-asserted-by":"crossref","unstructured":"J.R. Duvall, R.A. Bukhalid, N.M. Cetinbas, K.C. Catcott, Kelly L., K.W. Bentley, S. Clark, S. Clardy, S.D. Collins, A. Dirksen, et\u00a0al. (2022 Apr 8-13). XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022. 82.","DOI":"10.1158\/1538-7445.AM2022-3503"},{"key":"10.1016\/j.ymthe.2023.03.019_bib100","author":"Therapeutics"},{"key":"10.1016\/j.ymthe.2023.03.019_bib101","series-title":"A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Positive Solid Tumors","author":"Meric-Bernstam","year":"2020"},{"key":"10.1016\/j.ymthe.2023.03.019_bib102","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1535-7163.MCT-20-0237","article-title":"PF-06804103, A site-specific anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers","volume":"19","author":"Graziani","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib103","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10928-020-09702-3","article-title":"Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1","volume":"47","author":"Betts","year":"2020","journal-title":"J.\u00a0Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ymthe.2023.03.019_bib105","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2021.08.014","article-title":"DHES0815A, a novel antibody-drug conjugate targeting HER2\/neu, is highly active against uterine serous carcinomas in\u00a0vitro and in\u00a0vivo","volume":"163","author":"Tymon-Rosario","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib106","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P2-13-25","article-title":"A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer [abstract]","author":"Krop","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib107","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib108","author":"MSKCC"},{"key":"10.1016\/j.ymthe.2023.03.019_bib109","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","article-title":"ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers [abstract]","author":"Hamblett","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","article-title":"HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer","volume":"16","author":"Miller","year":"2016","journal-title":"BMC cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2012.04.008","article-title":"HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity","volume":"262","author":"Reynolds","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ymthe.2023.03.019_bib112","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/0008-5472.CAN-15-1518","article-title":"Dual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer","volume":"76","author":"Espelin","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib113","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1158\/1535-7163.MCT-15-0314","article-title":"Cyclophosphamide-mediated tumor priming for enhanced delivery and antitumor activity of HER2-targeted liposomal doxorubicin (MM-302)","volume":"14","author":"Geretti","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib114","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","article-title":"Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study","volume":"119","author":"Munster","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010154","article-title":"Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs","volume":"14","author":"D\u00edaz-Rodr\u00edguez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2023.03.019_bib119","article-title":"TAA013 a trastuzumab antibody drug conjugate phase I dose escalation study in recurrent her2 positive breast cancer [abstract]","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.03.019_bib120","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clbc.2021.11.006","volume":"22","author":"Chiradoni Thungappa","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ymthe.2023.03.019_bib121","author":"DEVELOPMENT"},{"key":"10.1016\/j.ymthe.2023.03.019_bib122","doi-asserted-by":"crossref","unstructured":"Li, H., and Li, H. A narrative review of the current landscape and future perspectives of HER2-targeting antibody drug conjugates for advanced breast cancer.Transl. Breast Cancer Res.,2, p.29","DOI":"10.21037\/tbcr-21-22"},{"key":"10.1016\/j.ymthe.2023.03.019_bib123","first-page":"1189","article-title":"Safety evaluation of antibody-drug-conjugates(ADC)HS630 on the central nervous system of rats","volume":"38","author":"Qian-qian","year":"2018","journal-title":"Chin. J. Pharm. Anal."},{"key":"10.1016\/j.ymthe.2023.03.019_bib125","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/1535-7163.MCT-17-0795","article-title":"MI130004, a novel antibody-drug conjugate combining trastuzumab with a molecule of marine origin, shows outstanding in\u00a0vivo activity against HER2-expressing tumors","volume":"17","author":"Avil\u00e9s","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib126","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1158\/1535-7163.MCT-20-0190","article-title":"A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels","volume":"19","author":"Barfield","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2023.03.019_bib127","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ymthe.2023.03.019_bib128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-021-00472-z","article-title":"Clinical development of new antibody-drug conjugates in breast cancer: to infinity and beyond","volume":"35","author":"Barroso-Sousa","year":"2021","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2023.03.019_bib129","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ymthe.2023.03.019_bib131","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.semdp.2022.07.003","article-title":"HER2-low breast cancers: current insights and future directions","volume":"39","author":"Zhang","year":"2022","journal-title":"Semin. Diagn. Pathol."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623001405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623001405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:07:08Z","timestamp":1761502028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623001405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1525001623001405"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.019","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}